naltrexone

P=N/A, N=567, Completed, University of Pennsylvania | Active, not recruiting --> Completed

P1, N=20, Recruiting, Yale University | Not yet recruiting --> Recruiting

P=N/A, N=5, Recruiting, Wake Forest University Health Sciences | Trial completion date: Apr 2026 --> Nov 2026 | Trial primary completion date: Feb 2026 --> Aug 2026

Naltrexone attenuated these neuroinflammatory changes. These findings highlight naltrexone's dual-action potential in addressing behavioral and neuroinflammatory consequences of chronic alcohol exposure, providing experimental evidence for its use in AUD, particularly with comorbid anxiety and depression.

Promising pharmacologic agents include medications for alcohol use disorder (e.g., naltrexone) and agents that may reduce liver fat and alcohol consumption concurrently, such as glucagon-like peptide-1 receptor agonists and FGF21 analogs. Despite growing recognition, MetALD remains under-studied, highlighting critical research gaps, including refined diagnostic criteria, noninvasive biomarkers, tailored clinical trials, and comprehensive outcome assessments. Addressing these gaps is essential to improve prognostication, risk stratification, and therapeutic outcomes in this increasingly prevalent clinical entity.

P2, N=250, Not yet recruiting, Go Medical Industries Pty Ltd | Trial completion date: Jan 2029 --> Jul 2029 | Trial primary completion date: Jan 2028 --> Jul 2028

P1/2, N=64, Not yet recruiting, Yale University

The mechanism involved downregulating oxidative stress and decreasing proinflammatory cytokines to levels at or below those of nondiabetic rats of the same sex. These findings support a mechanistic role for OGF receptor blockade in the reversal of diabetic dry eye.

P2, N=150, Recruiting, Central Institute of Mental Health, Mannheim | Not yet recruiting --> Recruiting

The plasma levels of the inflammatory markers such as interleukin-1β, interleukin-6, and tumor necrosis factor-α were comparable to the baseline values. In conclusion, 3D printed mucoadhesive gastric patch can be developed for long-active delivery of NTX.

In 2022, acitretin was commenced and uptitrated to 25 mg once daily...Other immunosuppressive agents such as methotrexate, ciclosporin and azathioprine have been described in the literature with varying efficacy...Naltrexone is postulated to work due to analgesic and anti-inflammatory effects. It is a well-tolerated treatment for severe HHD that has drastically improved both our patient's skin and his quality of life.

P2, N=45, Not yet recruiting, Johns Hopkins University